home / stock / nltx / nltx news

NLTX News and Press, Neoleukin Therapeutics Inc. From 04/16/20

Stock Information
Company Name: Neoleukin Therapeutics Inc.
Stock Symbol: NLTX
Market: NYSE
Menu
NLTX NLTX Quote NLTX Short NLTX News NLTX Articles NLTX Message Board
Get NLTX Alerts

News, Short Squeeze, Breakout and More Instantly...
NLTX - Neoleukin Therapeutics Announces Change of Location of Annual Meeting of Stockholders to Be Held May 5, 2020

SEATTLE, April 16, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design  de novo  protein therapeutics, announced today that, due to the public health im...
NLTX - Leerink rolls out lineup of bullish calls in premarket analyst action

Allogene Therapeutics (NASDAQ: ALLO ) initiated with Buy rating and $29 (28% upside) price target at SunTrust. More news on: Allogene Therapeutics, Inc., BridgeBio Pharma, Inc., Cerner Corporation, Healthcare stocks news, Stocks on the move, , Read more ...

NLTX - Neoleukin Therapeutics Provides Update on COVID-19 Impact on Corporate and Clinical Development Activities

SEATTLE, April 09, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design  de novo  protein therapeutics, today provided an update on the impacts of COVID-19...

NLTX - Medicenna's Potential Best-In-Class IL-2 Superkine Program Making Progress

Medicenna Therapeutics Corp. [TSX:MDNA] ( OTCQB:MDNAF ) is a Toronto based clinical-stage immuno-oncology company developing novel highly selective versions of IL-2, IL-4 and IL-13 Superkines. Superkines can be engineered as short or long-acting therapeutics or fused with cell-killing protei...
NLTX - Neoleukin Therapeutics, Inc. (NLTX) CEO Jonathan Drachman on Q4 2019 Results - Earnings Call Transcript

Neoleukin Therapeutics, Inc. (NLTX) Q4 2019 Earnings Conference Call March 12, 2020, 16:30 ET Company Participants Julie Rathbun - Communications Jonathan Drachman - CEO, President & Interim Chairman Kamran Alam - Interim CFO, VP, Finance & Corporate Secretary Conferen...

NLTX - Neoleukin Therapeutics EPS beats by $0.07

Neoleukin Therapeutics (NASDAQ: NLTX ): FY GAAP EPS of -$2.57 beats by $0.07 . More news on: Neoleukin Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

NLTX - Neoleukin Therapeutics Announces Year End Financial Results

- NL-201 IND Submission Expected by End of 2020 - - Company to host Conference Call Today, March 12, 2020 at 1:30 p.m. Pacific / 4:30 p.m. Eastern - SEATTLE, March 12, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical...
NLTX - Neoleukin Therapeutics Announces Appointment of Robert K. Ho as Chief Financial Officer

SEATTLE, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design  de novo  protein therapeutics, today announced the appointment of Robert Ho as C...

NLTX - Neoleukin Therapeutics to Present at Cowen and Company 40th Annual Health Care Conference

SEATTLE, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design  de novo  protein therapeutics, today announced that Jonathan Drachman, M.D., Chi...

NLTX - Citigroup sees 36% upside in Amarin in premarket analyst action

Neoleukin  Therapeutics (NASDAQ: NLTX ) initiated with Buy rating and $20 (82% upside) price target at Guggenheim. More news on: Xeris Pharmaceuticals, Inc., Neoleukin Therapeutics, Inc., Amarin Corporation plc, Healthcare stocks news, Stocks on the move, , Read more ...

Previous 10 Next 10